

Electronic Acknowledgement Receipt

EFS ID:	2665344
Application Number:	10524197
International Application Number:	
Confirmation Number:	4118
Title of Invention:	C-substituted tricyclic isoxazoline derivatives and their use as anti-depressants
First Named Inventor/Applicant Name:	Jose Ignacio Andres-Gil
Customer Number:	45511
Filer:	Stephanie A. Barbosa/D. McCarty
Filer Authorized By:	Stephanie A. Barbosa
Attorney Docket Number:	JANS-0075 (JAB1721USPCT)
Receipt Date:	03-JAN-2008
Filing Date:	10-FEB-2005
Time Stamp:	14:08:12
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$130
RAM confirmation Number	6987
Deposit Account	233050
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional fees required under 37 CFR 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	Jans-0075TransSuppReply.pdf	40872 6dbaa0f6c7b24c7f6411b059493035cd1d396e308	no	4

Warnings:

Information:

2		Jans-0075SuppReply.pdf	61803 70e4bda0b0e7310564bc94951305cd 9164657c	yes	9
---	--	------------------------	---	-----	---

Multipart Description/PDF files in .zip description

Document Description	Start	End
Amendment - After Non-Final Rejection	1	1
Claims	2	8
Applicant Arguments/Remarks Made in an Amendment	9	9

Warnings:

Information:

3	Terminal Disclaimer Filed	Jans-0075TerminalDisclaimerr.pdf	27605 t6b4777d50396d345533aaee54d19e5 e054261c	no	2
---	---------------------------	----------------------------------	--	----	---

Warnings:

Information:

4	Fee Worksheet (PTO-06)	fee-info.pdf	8239 45e71b640dabab5dd555524e99e2078af d4aae6fd	no	2
---	------------------------	--------------	---	----	---

Warnings:

Information:

Total Files Size (in bytes):	138519
------------------------------	--------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.